Overview

Safety and Pharmacokinetics of ODM-209

Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this first-in-human study is to evaluate safety and tolerability of ODM-209 and find the dose of ODM-209.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Orion Corporation, Orion Pharma